Eli Lilly and Company (NYSE:LLY - Get Free Report) fell 0.4% during trading on Friday . The company traded as low as $711.98 and last traded at $718.00. 809,465 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 3,365,092 shares. The stock had previously closed at $720.91.
Analysts Set New Price Targets
LLY has been the subject of a number of analyst reports. Citigroup cut their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Guggenheim lowered their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday. Morgan Stanley cut their price objective on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Finally, StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,012.00.
View Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Price Performance
The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $717.34 billion, a price-to-earnings ratio of 64.61, a P/E/G ratio of 1.40 and a beta of 0.51. The company's 50 day moving average is $835.24 and its 200-day moving average is $822.00.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Eli Lilly and Company
Large investors have recently added to or reduced their stakes in the stock. Highline Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 80.0% during the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after acquiring an additional 20 shares during the period. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $43,000. FPC Investment Advisory Inc. boosted its stake in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $48,000. Finally, Compass Financial Services Inc bought a new position in Eli Lilly and Company in the 4th quarter valued at approximately $50,000. Institutional investors and hedge funds own 82.53% of the company's stock.
Eli Lilly and Company Company Profile
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
